Curcumin and inflammatory bowel diseases: From in vitro studies to clinical trials

Fallahi, F. and Borran, S. and Ashrafizadeh, M. and Zarrabi, A. and Pourhanifeh, M.H. and Khaksary Mahabady, M. and Sahebkar, A. and Mirzaei, H. (2021) Curcumin and inflammatory bowel diseases: From in vitro studies to clinical trials. Molecular Immunology, 130. pp. 20-30.

Full text not available from this repository.
Official URL:


Inflammatory bowel diseases (IBDs) may result from mutations in genes encoding for innate immunity, which can lead to exacerbated inflammatory response. Although some mono-targeted treatments have developed in recent years, IBDs are caused through several pathway perturbations. Therefore, targeting all these pathways is difficult to be achieved by a single agent. Moreover, those mono-targeted therapies are usually expensive and may cause side-effects. These limitations highlight the significance of an available, inexpensive and multi-targeted dietary agents or natural compounds for the treatment and prevention of IBDs. Curcumin is a multifunctional phenolic compound that is known for its anti-inflammatory and immunomodulatory properties. Over the past decades, mounting experimental investigations have revealed the therapeutic potential of curcumin against a broad spectrum of inflammatory diseases including IBDs. Furthermore, it has been reported that curcumin directly interacts with many signaling mediators implicated in the pathogenesis of IBDs. These preclinical findings have created a solid basis for the assessment of the efficacy of curcumin in clinical practice. In clinical trials, different dosages e.g., 550 mg /three times daily-1month, and 1 g /twice times daily-6month of curcumin were used for patients with IBDs. Taken together, these findings indicated that curcumin could be employed as a therapeutic candidate in the treatment of IBDs. Moreover, it seems that overcome to current limitations of curcumin i.e., poor oral bioavailability, and poor oral absorption with using nanotechnology and others, could improve the efficacy of curcumin both in pre-clinical and clinical studies. © 2020 Elsevier Ltd

Item Type: Article
Additional Information: cited By 2
Uncontrolled Keywords: curcumin; antiinflammatory agent; curcumin, clinical trial (topic); human; in vitro study; inflammatory bowel disease; nonhuman; pathogenesis; preclinical study; priority journal; Review; animal; inflammatory bowel disease; phytotherapy; procedures, Animals; Anti-Inflammatory Agents; Clinical Trials as Topic; Curcumin; Drug Evaluation, Preclinical; Humans; Inflammatory Bowel Diseases; Phytotherapy
Subjects: WI Digestive System
Depositing User: eprints admin
Date Deposited: 03 Aug 2021 06:56
Last Modified: 03 Aug 2021 06:56

Actions (login required)

View Item View Item